WallStreetZenWallStreetZen

NASDAQ: PVLA
Palvella Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Palvella Therapeutics revenue was $1.35M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2024) ending on Sep 30, 2024 was $0.0, down N/A from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, PVLA annual revenue was $42.8M, with 65.3% growth year-over-year.

PVLA past revenue growth

How has PVLA's revenue growth performed historically?

Company
-97.15%
Industry
1,096.71%
Market
34.47%
PVLA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PVLA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PVLA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PVLA revenue history

Current Revenue
$1.4M
Current Earnings
-$16.0M
Current Profit Margin
-1,180%

Be the first to know when PVLA announces revenue.

PVLA Revenue History By Year

PVLA Yearly RevenuePVLA RevenuePVLA ChangePVLA Revenue Growth
2023-12-31$42.81M$16.91M+65.28%
2022-12-31$25.90M-$5.52M-17.56%
2021-12-31$31.42M$2.10M+7.14%
2020-12-31$29.32M-$16.96M-36.64%
2019-12-31$46.28M$17.18M+59.03%
2018-12-31$29.10M$3.83M+15.14%
2017-12-31$25.28M$19.44M+333.46%
2016-12-31$5.83M$2.90M+98.88%
2015-12-31$2.93M-$2.43M-45.35%
2014-12-31$5.37M-$7.06M-56.83%
2013-12-31$12.43MN/AN/A

1 of 1

Palvella Therapeutics Revenue FAQ

What was PVLA's revenue last quarter?

On Invalid Date, Palvella Therapeutics (NASDAQ: PVLA) reported Q3 2024 revenue of $0.00 up 100% year over year. In the same quarter last year, Palvella Therapeutics's revenue was $19.52 million.

What was Palvella Therapeutics's revenue in 2023?

Palvella Therapeutics's annual revenue for the twelve months ending Dec 31, 2023 was $42.81 million, a 65.28% increase year over year.

How much does Palvella Therapeutics make in a day?

Based on Palvella Therapeutics annual revenue for the past five years, PVLA makes an average of $96,291.51 per day.

What was Palvella Therapeutics's annual revenue growth in the past year?

As of Q1 2025, Palvella Therapeutics's revenue has grown -97.15% year over year. This is 1,193.85 percentage points lower than the US Biotechnology industry revenue growth rate of 1,096.71%. Palvella Therapeutics's revenue in the past year totaled $1.35 million.

How much does Palvella Therapeutics make in a year?

Palvella Therapeutics's revenue by year for the past five years is:
  • Palvella Therapeutics's revenue for the twelve months ending Dec 31, 2023 was $42.81 million, a 65.28% increase year over year.
  • Palvella Therapeutics's annual revenue for Dec 31, 2022 was $25.90 million, a 17.56% decrease from 2021.
  • Palvella Therapeutics's annual revenue for 2021 was $31.42 million, a 7.14% increase from 2020.
  • Palvella Therapeutics's annual revenue for 2020 was $29.32 million, a 36.64% decrease from 2019.
  • Palvella Therapeutics's annual revenue for 2019 was $46.28 million, a 59.03% increase from 2018.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.